Quick Answer
Tango Therapeutics, Inc. reported Total Revenue of $62.38 million for the year ending 2025.
- Tango Therapeutics, Inc. showed an increase of +48.3% in Total Revenue from 2024 to 2025.
- This data is from Tango Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$11.26 million | Q1 2021: $6.39 million | Q2 2021: $18.15 million | Q3 2021: $6.79 million | Q1 2022: $5.76 million | Q2 2022: $5.77 million | Q3 2022: $6.92 million | Q1 2023: $5.77 million | Q2 2023: $14.60 million | Q3 2023: $10.73 million | Q1 2024: $6.47 million | Q2 2024: $19.88 million | Q3 2024: $11.61 million | Q1 2025: $5.39 million | Q2 2025: $3.18 million | Q3 2025: $53.81 million.
- Over the full 6 years of available data (2020 to 2025), Tango Therapeutics, Inc.'s Total Revenue has grown by 714.8%.
- Historical annual values: Fiscal year 2025: $62.38 million | Fiscal year 2024: $42.07 million | Fiscal year 2023: $36.53 million | Fiscal year 2022: $24.86 million | Fiscal year 2021: $37.04 million | Fiscal year 2020: $7.66 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: